Compounded semaglutide vs Ozempic: what the shortage end actually means in 2025–2026.

From 2022 to late 2024, a combination of FDA-declared drug shortages and high list prices made compounded semaglutide a large, legally permitted, and practically important part of the GLP-1 access landscape. That landscape changed materially when the FDA announced the semaglutide shortage resolved in October 2024. The change didn't end all compounding immediately — but it moved the legal ground under 503B outsourcing facilities, triggered enforcement actions, and prompted ongoing litigation from 503A pharmacies seeking to preserve their compounding authority. This page explains what those distinctions mean and what the picture looks like in 2025–2026.

The three tiers of semaglutide in 2025–2026

Understanding the compounding debate requires keeping three legally distinct product categories separate in your mind at all times. They are not interchangeable, and conflating them is the primary source of consumer and researcher confusion in this space.

A compounded product is not a generic drug. This is a statutory fact, not just marketing copy. Generic drugs are FDA-approved; they have demonstrated bioequivalence to a reference listed drug; they are manufactured under cGMP at approved facilities. Compounded semaglutide has none of these. What it did have, during the shortage period, was a specific statutory authorisation under §503A/503B to produce copies of a shortlisted drug — and that authorisation ended when the shortage did.

How the FDA shortage system works: 503A and 503B

The legal framework for pharmaceutical compounding in the US was substantially revised by the Drug Quality and Security Act (DQSA) of 2013, which amended the FD&C Act to create two distinct compounding frameworks.

Section 503A — traditional compounding pharmacies. Licensed by state pharmacy boards. Can compound drugs for individual patients based on valid patient-specific prescriptions. Can compound drug copies if the drug is on the FDA shortage list or if the drug is not commercially available (e.g., it needs a specific dosage form or flavour for a patient). Cannot compound drugs that are essentially a copy of an FDA-approved drug outside these conditions. Cannot compound in bulk for general sale.

Section 503B — outsourcing facilities. Voluntarily registered with FDA (not state-licensed only). Can compound in bulk without patient-specific prescriptions and sell to hospitals, clinics, and licensed practitioners. Subject to cGMP requirements (stricter than 503A). Can compound drugs on the FDA shortage list during the shortage period. When a drug is removed from the shortage list, the specific shortage-based authorisation for 503B bulk compounding lapses.

October 2024 shortage resolution and its consequences

FDA published notice in October 2024 that the shortages for both semaglutide injection products (Ozempic and Wegovy) had been resolved — meaning Novo Nordisk had restored adequate supply to meet demand. This triggered the FD&C Act's shortage-resolution consequences:

• 503B outsourcing facilities: The shortage-compounding authorisation under §503B lapsed immediately upon shortage resolution. FDA issued compliance policy guidance establishing a wind-down period, after which 503B compounders were expected to cease producing semaglutide. FDA enforcement actions followed — some outsourcing facilities received warning letters; litigation was initiated by trade groups representing compounders.
• 503A pharmacies: The 503A situation is more legally contested. Compounders and their advocates argued that 503A pharmacies retain the ability to compound semaglutide for patient-specific prescriptions even outside shortage conditions, particularly where patients cannot obtain the branded product for reasons of access, affordability, or specific formulation needs. The FDA's position was that for FDA-approved drugs off the shortage list, compounding essentially a copy of the branded product (same API, same route, same indication) is not permitted under 503A. The case law and regulatory guidance on this is active; consult current counsel.
• Semaglutide sodium: FDA separately flagged formulations labelled as "semaglutide sodium" as not covered by the shortage compounding authorisation even during the shortage period, on the basis that sodium salt form is a different active ingredient from the semaglutide base in the approved products. This was the subject of specific warning letters and enforcement action targeting vendors who reframed their formulations using the sodium salt designation.

The USP semaglutide monograph (2024)

The United States Pharmacopeia (USP) published a semaglutide reference standard and draft monograph in 2024. This is a significant development for anyone evaluating either compounded or RUO semaglutide, because it establishes a published reference point against which test results can be compared. Before the monograph, evaluating a COA required comparison to vendor-specific specifications or to the NDA file — neither of which was publicly accessible.

The USP monograph specifies (in draft form):

• Identity: HPLC retention time matching USP reference standard.
• Assay (primary purity): ≥99.0% by RP-HPLC for drug-quality material. (RUO typical claims are ≥98%, which is below drug quality.)
• Related substances: Individual impurities < 0.5%; total impurities < 2%.
• Molecular identity: Mass-spec confirmation, [M+H]⁺ consistent with MW 4113.6 Da.
• Water content: ≤6% (Karl Fischer).
• Endotoxins: ≤5 EU/mg (LAL assay).

The practical utility: when evaluating a compounded semaglutide COA or an RUO vendor COA, you now have a public reference point. A COA that claims "98% purity by HPLC" does not meet the USP assay target of ≥99.0%, and a COA that lacks mass-spec identity, water content, and endotoxin data is materially incomplete relative to the pharmacopoeia standard. This does not make the RUO product pharmaceutical-grade — it makes the gap legible.

Quality comparison: branded vs compounded vs RUO

Ozempic and Wegovy are manufactured by Novo Nordisk under cGMP (current Good Manufacturing Practice) at FDA-inspected facilities. Every batch undergoes pre-release testing against the approved specification. The product has a validated stability profile, a regulated supply chain with proper cold storage, and a documented adverse-event reporting system. The USP/NF specifications in the NDA are the same ones the monograph is modelled on.

Compounded semaglutide from a 503A or 503B facility is manufactured under USP <797> (sterile compounding) standards, which are stricter than general pharmacy standards but less rigorous than cGMP. The compounding pharmacist or outsourcing facility typically purchases bulk API from a peptide synthesis vendor, reconstitutes or dilutes it, and fills vials or syringes. Quality checks are batch-specific but lack the pre-market approval, iterative manufacturing validation, and pharmacopoeia-level specification of the branded product. The API source matters enormously — not all bulk semaglutide API sourced by compounders has been independently verified for sequence fidelity, impurity profile, and endotoxin level.

Research-chemical semaglutide has no pharmaceutical manufacturing standards applied. The COA is only as reliable as the vendor's testing protocols and their choice of contract testing laboratory. The gap between "98% pure by HPLC" and "passes the USP monograph" is not just a number — it represents the difference between knowing the main peak is predominant and knowing the compound is what the label says, has no unsafe impurities, and has been tested against a validated reference.

Access and cost in 2025–2026

Before October 2024, compounded semaglutide was widely available at roughly $200–$400/month from 503B outsourcing facilities and telehealth-affiliated pharmacies, vs the $900–$1,300/month list price of branded Wegovy. The supply shortage also meant branded product was often literally unavailable. The shortage-resolution changes both dimensions: branded supply is now generally available, and the low-cost compounded alternative has significantly narrowed.

Manufacturer coupons, patient assistance programs, and some insurance coverage have improved branded drug affordability for some patients. But for the large segment of patients who used compounded semaglutide because branded product was either unaffordable or supply-constrained, the 2024–2025 transition is materially disruptive. The legislative and policy conversation about GLP-1 drug pricing and access is ongoing.

For the tirzepatide compounding picture, the parallel access story is covered in the dedicated compounded tirzepatide vs Mounjaro spoke.

What this means for researchers and RUO purchasers

If your interest in semaglutide is for legitimate in-vitro or in-vivo research (not for human use), the regulatory changes to pharmaceutical compounding do not directly affect the RUO market. Research-chemical vendors continue to sell semaglutide peptide under RUO framing; this is a separate regulatory regime from pharmaceutical compounding. What has changed is the quality signal environment: with the USP monograph published, there is now a public reference standard against which your vendor's COA can be compared. Requesting a COA that addresses:

• HPLC purity (primary peak ≥98%; ideally ≥99% for serious research purposes)
• Mass-spec identity confirmation ([M+H]⁺ ≈ 4114 Da)
• Individual impurity levels (<0.5% each)
• Water content (Karl Fischer, <6%)
• Endotoxin (LAL, <5 EU/mg if injectable use is contemplated)

…is now defensible against a published pharmacopoeia standard rather than vendor-specific specifications. This doesn't make RUO product pharmaceutical-grade, but it gives researchers a meaningful quality floor to require.

For context on the existing semaglutide evidence base that makes quality matter — the STEP trial program and SELECT — see the semaglutide research page. For the head-to-head comparison with tirzepatide, see semaglutide vs tirzepatide. For dosing schedules derived from the approved label, see the semaglutide dosing spoke.